Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ELAN
stocks logo

ELAN

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
1.09B
+7.27%
0.111
-21.02%
1.27B
+6.66%
0.349
-5.78%
1.30B
+5.15%
0.305
+17.38%
Estimates Revision
The market is revising Upward the revenue expectations for Elanco Animal Health Incorporated (ELAN) for FY2025, with the revenue forecasts being adjusted by 1.71% over the past three months. During the same period, the stock price has changed by 19.32%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.71%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+6.76%
In Past 3 Month
Stock Price
Go Up
up Image
+19.32%
In Past 3 Month
Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 25.13 USD with a low forecast of 23.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Analyst Rating
Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 25.13 USD with a low forecast of 23.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
1 Hold
0 Sell
Strong Buy
Current: 21.990
sliders
Low
23.00
Averages
25.13
High
27.00
Current: 21.990
sliders
Low
23.00
Averages
25.13
High
27.00
KeyBanc
initiated
$27
2025-11-20
Reason
KeyBanc
Price Target
$27
2025-11-20
initiated
Reason
KeyBanc initiated coverage of Elanco with an Overweight rating and $27 price target.
KeyBanc
Overweight
initiated
$27
2025-11-20
Reason
KeyBanc
Price Target
$27
2025-11-20
initiated
Overweight
Reason
KeyBanc initiated coverage of Elanco with an Overweight rating and $27 price target. The firm expects success of the company's recent product launches to boost revenue growth and expand margins, while acknowledging challenges in displacing incumbent treatments, the analyst tells investors in a research note. KeyBanc adds that it sees a significant reduction in Elanco's leverage and looks to further improvement from increasing cash flows.
Piper Sandler
David Westenberg
Neutral
upgrade
$18 -> $24
2025-11-10
Reason
Piper Sandler
David Westenberg
Price Target
$18 -> $24
2025-11-10
upgrade
Neutral
Reason
Piper Sandler analyst David Westenberg raised the firm's price target on Elanco to $24 from $18 following quarterly results. The firm keeps a Neutral rating on the shares.
UBS
Andrea Alfonso
Buy
maintain
$25 -> $27
2025-11-06
Reason
UBS
Andrea Alfonso
Price Target
$25 -> $27
2025-11-06
maintain
Buy
Reason
UBS analyst Andrea Alfonso raised the firm's price target on Elanco to $27 from $25 and keeps a Buy rating on the shares. While there was plenty to like about the Q3 report, expectations are "fairly" lofty, the analyst tells investors in a research note.
Stifel
Buy
maintain
$23 -> $27
2025-11-05
Reason
Stifel
Price Target
$23 -> $27
2025-11-05
maintain
Buy
Reason
Stifel raised the firm's price target on Elanco (ELAN) to $27 from $23 and keeps a Buy rating on the shares. Elanco's stock currently trades at a premium to Zoetis (ZTS), but it is now expected to grow faster in 2025 relative to the market leader, the analyst tells investors. "More importantly," Elanco's margins are half of Zoetis' and the margin expansion opportunity is "significant" over the next 12-24 months, which should allow for EBITDA growth to outstrip Zoetis, the analyst added in a post-Q3 note.
UBS
Buy
maintain
$19 -> $25
2025-10-20
Reason
UBS
Price Target
$19 -> $25
2025-10-20
maintain
Buy
Reason
UBS raised the firm's price target on Elanco to $25 from $19 and keeps a Buy rating on the shares. UBS favors Elanco into the print and foresees EBITDA upside, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Elanco Animal Health Inc (ELAN.N) is 23.04, compared to its 5-year average forward P/E of 19.47. For a more detailed relative valuation and DCF analysis to assess Elanco Animal Health Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
19.47
Current PE
23.04
Overvalued PE
26.27
Undervalued PE
12.67

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
14.34
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
17.59
Undervalued EV/EBITDA
11.10

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.97
Current PS
0.00
Overvalued PS
2.75
Undervalued PS
1.19
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ELAN News & Events

Events Timeline

(ET)
2025-11-21
13:38:20
Elanco Granted FDA Emergency Use Authorization for Credelio CAT
select
2025-11-05 (ET)
2025-11-05
06:33:37
Elanco projects Q4 adjusted EPS between 9c and 12c, below consensus estimate of 14c.
select
2025-11-05
06:32:33
Elanco increases FY25 adjusted EPS forecast to 91c-94c, matching consensus at 91c
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-27PRnewswire
Neurizon Appoints Elanco Executive Justine Conway as Board Observer
  • Strengthened Strategic Partnership: Neurizon's appointment of Elanco's Global Head of Business Development, Justine Conway, as a Board Observer further solidifies its collaboration with Elanco, which is expected to enhance the clinical development and global commercialization of NUZ-001.
  • Key Milestone Achieved: This appointment follows Neurizon's exclusive global licensing agreement for Monepantel with Elanco, ensuring ongoing access to critical animal safety and manufacturing data, which are foundational for future clinical trials and regulatory approvals.
  • Industry Expertise Introduced: Conway brings over 20 years of experience in the animal health and healthcare sectors, having held senior roles at Macquarie Bank and Bank of America Merrill Lynch, and her extensive industry knowledge will provide strategic support to Neurizon.
  • Clinical Trial Preparation: Conway's involvement will assist Neurizon in entering the HEALEY ALS Platform Trial, which is expected to accelerate the late-stage development and market entry of NUZ-001, enhancing the company's competitiveness in neurodegenerative disease treatments.
[object Object]
Preview
5.0
11-27Newsfilter
Neurizon Appoints Elanco Executive as Board Observer to Enhance Strategic Partnership
  • Strengthened Strategic Partnership: Neurizon appoints Justine Conway, Elanco's Global Head of Business Development, as a Board Observer, further solidifying its collaboration with Elanco, which is expected to accelerate the clinical development of NUZ-001.
  • Key Milestone Achieved: This appointment follows Neurizon's exclusive global licensing agreement for Monepantel with Elanco, ensuring ongoing access to critical animal safety and manufacturing data, which are foundational for future clinical trials and market entry.
  • Industry Expertise Introduced: Conway brings over 20 years of experience in the healthcare sector, having held senior roles at Macquarie Bank and Bank of America Merrill Lynch, and her extensive background will provide Neurizon with valuable strategic insights.
  • Clinical Trial Preparation: Conway's involvement will support Neurizon's preparations for entry into the HEALEY ALS Platform Trial this quarter, further advancing the global commercialization efforts for NUZ-001.
[object Object]
Preview
5.0
11-27PRnewswire
Elanco executive appointed as Neurizon's Board Observer

  • Appointment of Board Observer: Neurizon Therapeutics has appointed Ms. Justine Conway as a Board Observer, representing Elanco Animal Health, to strengthen their partnership and governance framework.

  • Significant Licensing Agreement: The appointment follows a global license agreement for Monepantel, which supports Neurizon's regulatory foundations and access to critical data for future clinical trials and market entry.

  • Ms. Conway's Expertise: With over 20 years in the healthcare sector, Ms. Conway brings extensive experience in business development, strategic partnerships, and M&A transactions, which will aid Neurizon in advancing its lead drug candidate, NUZ-001.

  • Focus on ALS Treatment: Neurizon is dedicated to developing NUZ-001 for ALS treatment, aiming to accelerate access to effective therapies for patients while exploring broader applications for neurodegenerative diseases.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Elanco Animal Health Inc (ELAN) stock price today?

The current price of ELAN is 21.99 USD — it has decreased -0.86 % in the last trading day.

arrow icon

What is Elanco Animal Health Inc (ELAN)'s business?

Elanco Animal Health Incorporated is an animal health company delivering products and services to prevent and treat disease in farm animals and pets. The Company's product portfolio is sold in more than 90 countries and serves animals across many species, primarily dogs and cats (collectively, pet health) and cattle, poultry, swine, and sheep (collectively, farm animal). It has a diverse portfolio of products marketed under approximately 200 brands, including products for both pets and farm animals. The Company's global pet health portfolio is focused on parasiticides, vaccines and therapeutics. Its pet health products include Advantage Family, Atopica, Credelio Family, Drontal Family, Galliprant, Interceptor Plus, Milbemax, Onsior, Seresto, Trifexis, and TruCan. Its farm animal products include AviPro, Baytril, Catosal, Denagard, Experior, Hemicell, Maxiban/Monteban, Pulmotil, Rumensin, and Surmax. Its customers include consultants, veterinarians, farm animal producers and resellers.

arrow icon

What is the price predicton of ELAN Stock?

Wall Street analysts forecast ELAN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ELAN is 25.13 USD with a low forecast of 23.00 USD and a high forecast of 27.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Elanco Animal Health Inc (ELAN)'s revenue for the last quarter?

Elanco Animal Health Inc revenue for the last quarter amounts to 1.14B USD, increased 10.39 % YoY.

arrow icon

What is Elanco Animal Health Inc (ELAN)'s earnings per share (EPS) for the last quarter?

Elanco Animal Health Inc. EPS for the last quarter amounts to -0.07 USD, decreased -109.59 % YoY.

arrow icon

What changes have occurred in the market's expectations for Elanco Animal Health Inc (ELAN)'s fundamentals?

The market is revising Upward the revenue expectations for Elanco Animal Health Incorporated (ELAN) for FY2025, with the revenue forecasts being adjusted by 1.71% over the past three months. During the same period, the stock price has changed by 19.32%.
arrow icon

How many employees does Elanco Animal Health Inc (ELAN). have?

Elanco Animal Health Inc (ELAN) has 9000 emplpoyees as of December 05 2025.

arrow icon

What is Elanco Animal Health Inc (ELAN) market cap?

Today ELAN has the market capitalization of 10.93B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free